UCB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123 EUR | +3.58% |
|
+2.12% | +55.89% |
| Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
Presenter SpeechAntje Witte (Executives)Good morning, good afternoon to the call, Capital Mark...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
123
EUR
Average target price
125.5
EUR
Spread / Average Target
+2.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.89% | 25.14B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B | |
| -3.16% | 8.62B |
- Stock Market
- Equities
- UCB Stock
- News UCB
- Transcript : UCB SA, Zogenix, Inc. - M&A Call